Taiho Ventures has supplied a $10m extension for Caltech spinout Axial Biotherapeutics’ series B, bringing the total to $35m.

Axial Biotherapeutics, a US-based biotechnology developer spun out of California Institute of Technology (Caltech), boosted its series B round to $35m on Thursday following a $10m extension provided by pharmaceutical firm Taiho. Taiho supplied the money through its corporate venturing arm, Taiho Ventures. Axial closed an initial $25m tranche in February 2019 led by Health…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.